Navigation Links
Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD)
Date:9/3/2008

September is National Vascular Disease Awareness Month

CHARLOTTESVILLE, Va., Sept. 3 /PRNewswire/ -- Diffusion Pharmaceuticals LLC, a clinical-stage drug-development company commercializing new drugs for the treatment of unmet medical needs, announced today that it has begun to enroll patients in a Phase I/II clinical trial of its lead drug candidate trans sodium crocetinate (TSC). The trial, designated NCT00725881 on the clinicaltrials.gov Website, is investigating TSC as a treatment for peripheral arterial disease (PAD) patients who experience the severe leg pain known as intermittent claudication. According to the PAD Coalition, approximately 8 million Americans suffer from the disease. Results from the trial are expected to be announced in early 2010.

This double-blinded, placebo-controlled trial will randomize up to 48 patients at five research sites in the U.S. Primary clinical endpoints of the study are peak walking time and claudication onset time, as demonstrated by exercise treadmill tests. Both endpoints are well-accepted by the medical community and regulatory authorities as reliable indicators of efficacy in intermittent claudication clinical trials. Safety and pharmacokinetic assessments are also being conducted during the trial.

"In addition to advancing a much-needed treatment for peripheral arterial disease patients, this Phase I/II study will also help demonstrate TSC's potential to treat other diseases related to cellular oxygen deprivation," says David G. Kalergis, JD/MBA, Chief Executive Officer of Diffusion Pharmaceuticals. "Such proof-of-concept in humans is a critical step in the advancement of our novel pharmaceutical and will support our plans to apply it to treatments for a broad range of unmet medical needs affecting millions of patients annually."

TSC is the company's lead candidate in a family of first-in-class compounds, representing a new approach to the treatment of conditions characterized b
'/>"/>

SOURCE Diffusion Pharmaceuticals LLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies
2. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
3. Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000
4. Addrenex Pharmaceuticals New Hires Further Company Goal to Identify New Drugs for Adrenergic Regulation
5. Vion Pharmaceuticals Enters Into Agreement With HOVON to Conduct a Phase III Clinical Trial of Cloretazine(R) in Combination With Frontline AML and MDS Therapy
6. Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome)
7. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
8. Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin Capsule
9. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
10. Oramed Pharmaceuticals to Hold Conference Call on August 6 to Present Results of Phase 2A Oral Insulin Capsule Clinical Trials
11. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... the leading health care supply chain expertise, analytics and ... national contracts that expand its portfolio to provide hospital ... These include manufacturer product and service agreements, as well ... IT consulting support. New Novation agreements ...
(Date:1/15/2014)... Jan. 15, 2014 Massachusetts General Hospital (MGH), ... AMGN ) announced today that they have launched ... new therapeutic targets and develop novel therapies for ... affects millions worldwide. The MGH-Broad-Amgen collaboration brings together ...
(Date:1/15/2014)... 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will ... Journal of Drugs in Dermatology (JDD) at ... The event is January 17-20, 2014, at the Omni Orlando Resort ... The ODAC is a distinguished event that ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
(Date:7/11/2014)... TX (PRWEB) July 11, 2014 Plasma ... of blood products industry. Although the closure of 16 ... major disruption to domestic blood products market, the total ... 2.8% year on year and total lot release volume ... due to stock consumption, insufficient utilization of new plasma ...
(Date:7/11/2014)... Even the hot Texas sun won’t keep ... . The school had previously invested in a ... from APCPLAY, but recently asked for an innovative solution to ... Godley Elementary School chose a Rectangular Shade from APCPLAY as ... on their playground. The shade measures 24’W x 34’H ...
(Date:7/11/2014)... Based in Pearland, Prime Urgent Care has ... County and surrounding counties. Recently, it improved access to ... from Northbound Highway 288 and Feeder Road. , Prime ... get low-cost urgent care of high quality. Although low-cost ... that can match the quality service level of the ...
(Date:7/10/2014)... July 10, 2014 Fatigue, lack ... an increasing number of accidents in the workplace, ... Reboot. The articles highlight safety issues that contribute ... million accidents occur on the job annually, according ... continue to explore "preventable workplace accidents." , Safety ...
(Date:7/10/2014)... July 11, 2014 According to ... Market by Platforms (Land, Airborne, Naval), Application (Software ... & by Geography (North America, Asia-Pacific, Europe, the ... (2014-2019)", published by MarketsandMarkets, the market is estimated ... expected to register a CAGR of 5.56% to ...
Breaking Medicine News(10 mins):Health News:Chinese Blood Product Industry Report 2014-2017 Focuses Plasma Volume & Stations Says A New Research Available at ChinaMarketResearchReports.com 2Health News:Chinese Blood Product Industry Report 2014-2017 Focuses Plasma Volume & Stations Says A New Research Available at ChinaMarketResearchReports.com 3Health News:Chinese Blood Product Industry Report 2014-2017 Focuses Plasma Volume & Stations Says A New Research Available at ChinaMarketResearchReports.com 4Health News:Cool Fun Under the Texas Sun: Godley Elementary School Purchases Shade Structure from APCPLAY© 2Health News:Prime Urgent Care Announces New Access to the Clinic, Available from Northbound Highway 288 2Health News:Safety Reboot Magazine Focuses on: Why Extended Hours is Dangerous in the Workplace; Why Custodial Work Can be Dangerous; and Improving Safety for Roofers 2Health News:Safety Reboot Magazine Focuses on: Why Extended Hours is Dangerous in the Workplace; Why Custodial Work Can be Dangerous; and Improving Safety for Roofers 3Health News:Portable Communication Systems Market Projected to Reach $39.52 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Portable Communication Systems Market Projected to Reach $39.52 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Portable Communication Systems Market Projected to Reach $39.52 Billion by 2019 - New Report by MarketsandMarkets 4
... artemisinin yield from the herb Artemisia annua by specifying ... ,The two developments could bring down the ... Organization to treat malaria. Over 100 countries use it ... the drug chloroquine. ,A study, published in ...
... Legionnaires’ disease. // ,Jack Russell was admitted to ... of the bacteria Legionella pnuemophila, which causes the disease. ... It takes its name from the first known outbreak, which ... the Pennsylvania Department of the American Legion in 1976. ...
... of Pennsylvania School of Veterinary Medicine have derived uniparental ... eggs or two// sperm - and, for the first ... with healthy cells in adult mice. Their ... in an adult organ and could provide a less ...
... genes associated with the risk of developing Type II ... at risk a step closer. ,Researchers have ... that correspond to a risk of developing this life ... nearly 400,000 mutations in nearly 6,500 people. ...
... composer is just one of many blind people around the ... , Scientists working for the Doheny Eye ... a previous invention released in 2002; a prototype artificial retina. ... its successor, the Argus II Retinal Prosthesis System. ...
... come out with a device which is likely// to ... control issues. ,They have named this ... circuit in spinal cord which is responsible for the ... sustain continence. This device is extremely useful in patients ...
Cached Medicine News:Health News:Scientists Boost Production of Cheap Malaria Drugs 2Health News:Convict Felled by Legionnaires 2Health News:'single–parent' stem cells to replace adult mice organ 2Health News:'single–parent' stem cells to replace adult mice organ 3Health News:Genetic Test for Type II Diabetes Moves Closer 2Health News:Genetic Test for Type II Diabetes Moves Closer 3Health News:Bionic Eye may Restore Sight to the Blind 2Health News:Bladder Pacemaker For Incontinence 2Health News:Bladder Pacemaker For Incontinence 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: